Headlands Research, a leading multinational network of clinical trial sites, announced the acquisition of Trial Management Associates (TMA), a multi-site clinical research company with locations in North and South Carolina.
Financial terms weren’t disclosed.
The Headlands Research network now includes 21 sites across the United States and Canada, extending the network's southeastern US geographical reach.
"The acquisition of TMA further demonstrates our commitment to strategic growth," said Kyle Burtnett, CEO of Headlands Research.
Burtnett also said, "By adding TMA to our ever-expanding network of clinical trial sites, we are providing sponsors with more geographic options, larger and more diverse participant pools, and a greater depth of knowledge in two of our core clinical areas."
TMA is headquartered in Wilmington, North Carolina, with an additional location in Myrtle Beach, South Carolina.
Officials said TMA, led by President Phil Dattilo, brings significant experience across various therapeutic specialties, including vaccines, endocrinology, and more, complementing Headlands Research's existing areas of focus.
The officials said TMA's experienced team and strong relationships with industry-leading sponsors and clinical research organizations further bolster Headlands Research's strategic vision of accelerating clinical development and improving patient outcomes by leveraging best-in-class research infrastructure and expertise.
"The missions of TMA and Headlands Research are synchronous: to improve lives by advancing innovative medical therapies," said Phil Dattilo, TMA president.
Dattilo added, "Joining the Headlands Research family allows TMA to scale our capabilities, share best practices, and combine expertise in ways that will be of great value to our sponsors and participants."
